Lifecore Biomedical
LFCR
98 hedge funds and large institutions have $287M invested in Lifecore Biomedical in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 30 increasing their positions, 38 reducing their positions, and 11 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
22% more capital invested
Capital invested by funds: $235M → $287M (+$51.7M)
7% more funds holding
Funds holding: 92 → 98 (+6)
1.15% more ownership
Funds ownership: 86.68% → 87.83% (+1.1%)
21% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 38
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $116K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$4.26M |
| 2 |
2L
22NW LP
Seattle,
Washington
|
+$3.59M |
| 3 |
ICM
ISZO Capital Management
New York
|
+$2.69M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.72M |
| 5 |
TAM
Tocqueville Asset Management
New York
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Acuitas Investments
Seattle,
Washington
|
-$2.52M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$2.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.77M |
| 4 |
BlackRock
New York
|
-$1.61M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$893K |
LFCR Hedge Fund Activity: Q4 2021 in Review
98 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q4 2021, worth a combined $287M — up 22% from $235M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new LFCR positions and 11 closed out — a net gain of 6 holders — while 30 added to existing stakes and 38 trimmed.
The largest buyer was Assenagon Asset Management, adding an estimated $4.26M. The largest seller was Acuitas Investments, exiting entirely with an estimated $2.52M sold.
- 98 institutional investors held Lifecore Biomedical (LFCR) as of Q4 2021, up from 92 in Q3 2021.
- Funds reported $287M of Lifecore Biomedical stock for Q4 2021, up 22% quarter-over-quarter.
- 17 funds opened new Lifecore Biomedical positions in Q4 2021 and 11 closed out, a net change of +6 holders.
- The largest Lifecore Biomedical buyer in Q4 2021 was Assenagon Asset Management, an estimated $4.26M added.
- The largest Lifecore Biomedical seller in Q4 2021 was Acuitas Investments, an estimated $2.52M sold.
Based on aggregated 13F filings for Q4 2021.